Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,552 across all filing types
Latest filing 2023-05-13 Regulatory Filings
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Shareholders meeting
Regulatory Filings
2023-05-13 English
The Scrutinizer's Report issued by M/s. MMJB & Associates LLP Company Secretaries on the remote e-voting conducted from 08th May 2023 to 10th May 2023 and e-voting at the Annual General ....
Regulatory Filings
2023-05-13 English
Shareholders meeting
AGM Information Classification · 100% confidence The document is a summary of proceedings from the 67th Annual General Meeting (AGM) of Sanofi India Limited held on 11th May 2023. It includes details about the meeting format (video conferencing), voting methods, and resolutions approved by shareholders such as adoption of financial statements, dividend declarations, re-appointment of a director, and remuneration approvals. The document is addressed to stock exchanges and signed by the company secretary. The content is a summary of the AGM proceedings rather than the full AGM materials or the full annual report. The document length is short (2985 characters), and it serves as an official record of the AGM outcomes. Therefore, it fits the category of AGM Information (AGM-R).
2023-05-12 English
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, The summary of proceedings of the 67th Annual General Meeting of the Company ....
AGM Information Classification · 95% confidence The document is a summary of proceedings from the 67th Annual General Meeting (AGM) of Sanofi India Limited held on 11th May 2023. It includes details about the meeting format (video conferencing), voting methods, and resolutions approved by shareholders such as adoption of financial statements, dividend declarations, re-appointment of a director, and remuneration approvals. The document is relatively short (2985 characters) and serves as a formal record of the AGM proceedings rather than the full AGM materials or presentations. It is not a full Annual Report, Earnings Release, or any other detailed financial or management report. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or summaries of the meeting proceedings.
2023-05-12 English
Copy of Newspaper Publication
Interim / Quarterly Report Classification · 95% confidence The document is a letter dated 12th May 2023 from Sanofi India Limited addressed to stock exchanges, enclosing copies of newspaper publications of financial results for the quarter ended 31st March 2023. The text includes an extract of unaudited financial results for the quarter ended 31st March 2023, with key financial figures such as total income, net profit before and after tax, and earnings per share. The document explicitly states that these are unaudited financial results for a quarter, which aligns with an Interim / Quarterly Report. The document is over 5,000 characters and contains substantive financial data, not just an announcement or a certification. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2023
2023-05-12 English
Please find enclosed copies of the Newspaper publication of financial results for quarter ended 31st March 2023, of the Company published today i.e.12th May,2023, in Business Standard and Sakal.
Earnings Release Classification · 95% confidence The document is a letter dated 12th May 2023 from Sanofi India Limited addressed to stock exchanges (BSE and NSE) enclosing copies of newspaper publications of financial results for the quarter ended 31st March 2023. The text includes an extract of unaudited financial results for the quarter ended 31st March 2023, with key financial figures such as total income, net profit before and after tax, and earnings per share. The document explicitly states that the results are unaudited and are an extract of the detailed format filed under SEBI regulations. The document is essentially a public notice and newspaper publication of quarterly financial results, not the full detailed quarterly report itself. It is a formal announcement of financial results rather than a comprehensive interim or quarterly report containing full financial statements and analysis. Therefore, it fits best under Earnings Release (ER), which covers initial announcements of quarterly financial results with key highlights only. Q1 2023
2023-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.